HomeCompareIKNA vs PM

IKNA vs PM: Dividend Comparison 2026

IKNA yields 11.66% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PM wins by $6.4K in total portfolio value· pulled ahead in Year 6
10 years
IKNA
IKNA
● Live price
11.66%
Share price
$17.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.2K
Annual income
$2,414.13
Full IKNA calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — IKNA vs PM

📍 PM pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIKNAPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IKNA + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IKNA pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IKNA
Annual income on $10K today (after 15% tax)
$990.68/yr
After 10yr DRIP, annual income (after tax)
$2,052.01/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, PM beats the other by $66.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IKNA + PM for your $10,000?

IKNA: 50%PM: 50%
100% PM50/50100% IKNA
Portfolio after 10yr
$46.4K
Annual income
$2,453.07/yr
Blended yield
5.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

IKNA
Analyst Ratings
4
Buy
1
Hold
Consensus: Buy
Price Target
$1.33
-92.2% upside vs current
Range: $1.33 — $1.33
Altman Z
60.4
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IKNA buys
0
PM buys
0
No recent congressional trades found for IKNA or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIKNAPM
Forward yield11.66%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$43.2K$49.6K
Annual income after 10y$2,414.13$2,492.02
Total dividends collected$17.8K$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$1.33$194.30

Year-by-year: IKNA vs PM ($10,000, DRIP)

YearIKNA PortfolioIKNA Income/yrPM PortfolioPM Income/yrGap
1$11,866$1,165.50$11,648$408.29+$218.00IKNA
2$13,989$1,292.45$13,589$495.90+$400.00IKNA
3$16,392$1,424.02$15,877$603.21+$515.00IKNA
4$19,099$1,559.51$18,580$734.88+$519.00IKNA
5$22,134$1,698.17$21,781$896.75+$353.00IKNA
6← crossover$25,522$1,839.29$25,578$1,096.12$56.00PM
7$29,291$1,982.13$30,092$1,342.17$801.00PM
8$33,467$2,125.99$35,470$1,646.46$2.0KPM
9$38,080$2,270.21$41,892$2,023.58$3.8KPM
10$43,160$2,414.13$49,578$2,492.02$6.4KPM

IKNA vs PM: Complete Analysis 2026

IKNAStock

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Full IKNA Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this IKNA vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IKNA vs SCHDIKNA vs JEPIIKNA vs OIKNA vs KOIKNA vs MAINIKNA vs MOIKNA vs BTIIKNA vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.